Pathology: breast cancer - adjuvant; la/mBC - HR-positive - 1st line (L1); la/mBC - HR-positive - 2nd line (L2);
| breast cancer - adjuvant | la/mBC - HR-positive - 1st line (L1) | la/mBC - HR-positive - 2nd line (L2) | |||
| MonarchE, 2021 | MONARCH 3, 2017 | MonarchE, 2021 | MONARCH 2, 2020 | ||
| abemaciclib plus endocrine therapy | 2 | T1 | T1 | ||
| abemaciclib plus fulvestrant | 1 | T1 | |||
| abemaciclib plus aromatase inhibitor | 1 | T1 | |||
| endocrine therapy | 0 | T0 | T0 | ||
| fulvestrant | 0 | T0 | |||
| aromatase inhibitor | 0 | T0 | |||